Raltegravir was the first integrase inhibitor to become available, and it opened the way for a class that now anchors modern HIV treatment. It remains in use today in particular situations. This guide explains what raltegravir is, how it works, where it fits in current treatment, and the points a treating doctor keeps under review.
Raltegravir is often abbreviated to RAL, and it belongs to the same class as dolutegravir and bictegravir.
| Important note This article is general information about medicines used in HIV care. It does not include dosing instructions and is not a substitute for medical advice. All HIV medicines are prescription-only and are selected, started, and changed by a qualified doctor. |
Quick Summary / Key Takeaways
|
Raltegravir belongs to the integrase inhibitor class described in the guide to integrase inhibitors. It is not used on its own, but forms part of a combination regimen, usually alongside two NRTIs.
HIV needs an enzyme called integrase to insert its genetic material into the DNA of a human immune cell. Raltegravir blocks that enzyme. With this step interrupted, the virus cannot establish itself inside the cell or produce new copies, and the amount of virus in the body falls over time.
Raltegravir was the first medicine of its class to reach patients, and its arrival marked an important advance in HIV treatment. It demonstrated how effective this class could be, which paved the way for later integrase inhibitors that offer once-daily single-tablet options.
For most people beginning treatment today, current guidance points to regimens built around dolutegravir, as described in first-line ART regimens explained.
| Benefit | What it means in practice |
| Well tolerated | Generally causes few troublesome effects |
| Few interactions | Works alongside many other medicines with less adjustment |
| Established record | The longest track record of any integrase inhibitor |
| Effective | Strong rates of viral suppression when taken consistently |
Raltegravir is generally well tolerated. Where effects occur, they are usually mild and may include:
General approaches to early effects are covered in managing common ART side effects.
Raltegravir remains effective, and newer members of the class such as dolutegravir and bictegravir are often preferred because they suit once-daily single-tablet regimens. The comparison across the class is set out in the guide to integrase inhibitors, with a dedicated guide to bictegravir.
| Myth | Fact |
| Raltegravir can be taken on its own. | It is used in combination with other ART medicines. |
| Being the first of its class means it is outdated. | It remains effective and useful in particular situations. |
| All integrase inhibitors are identical. | They share a mechanism but differ in dosing and combinations. |
| Weight change affects everyone on this class. | It is reported in some people and is monitored at follow-up. |
| Raltegravir interacts with everything. | It has relatively few interactions, which is one of its advantages. |
ย
| When to Consult a Doctor Medical advice is appropriate before starting or changing raltegravir, where side effects appear or persist, and where other medicines or supplements are being taken. Support is available through HIV treatment and ART care. |
Raltegravir was the first integrase inhibitor and remains a well tolerated, effective option with few interactions. While newer medicines in the class are often preferred for once-daily single-tablet treatment, raltegravir retains a defined place in HIV care, decided in each case by the treating doctor
Raltegravir is an integrase inhibitor used as part of combination HIV treatment. Today it is used in particular situations, including where its low potential for interactions is helpful alongside treatment for other conditions.
It blocks an enzyme called integrase, which HIV needs to insert its genetic material into human immune cells. With that step interrupted, the virus cannot multiply, and the amount of virus in the body falls over time.
Yes. Raltegravir was the first medicine of the integrase inhibitor class to become available, and its arrival paved the way for later options such as dolutegravir and bictegravir.
It is generally well tolerated. Where effects occur they are usually mild and may include headache, nausea, difficulty sleeping, or tiredness, which often settle as the body adjusts.
Newer options such as dolutegravir and bictegravir suit once-daily single-tablet regimens, which simplify treatment. Raltegravir remains effective and is chosen where its particular profile is suitable.
Raltegravir has relatively few interactions, which is one of its advantages. Mineral-containing products can affect it, so a treating doctor advises on timing and reviews everything being taken.
No. It is always used as part of a combination regimen, usually alongside two NRTIs, so that HIV is blocked at more than one stage of its life cycle.
Yes. Raltegravir remains an effective antiretroviral medicine with a long track record. The preference for newer options reflects the convenience of single-tablet regimens rather than a lack of effectiveness.
+91 98925 15959
Before You Go
The HIV Test Kit Is Still FREE
A private HIV self-test, delivered in plain packaging. Result in 20 minutes, at home. No cost, no clinic visit, and a TAAL+ doctor on call whichever way it goes.
Offer valid only in India till 30 September 2026. T&Cs apply.
